background: immunotoxins are comprised of both the cell targeting and the cell killing moieties. we previously established a new immunotoxin, i.e. shiga toxin granulocyte macrophage-colony stimulating factor (stxa1-gm-csf), comprises of catalytic domain of stx, as a killing moiety and gm-csf, as a cell targeting moiety. in this study, the ability of the immunotoxin to induce apoptosis and doubl...

Addition of Shiga toxin 2 to human bone marrow or cord blood cell culture induced macrophage-granulocyte colonies. Although Shiga toxin 2 alone induced colonies mainly composed of macrophages, it induced colonies mainly consisting of granulocytes when combined with physiological doses of interleukin-1beta, granulocyte colony-stimulating factor, or stem cell factor with interleukin-3.

fusion of two genes at dna level produces a single protein, known as a chimeric protein. immunotoxins are chimeric proteins composed of specific cell targeting and cell killing moieties. bacterial or plant toxins are commonly used as the killing moieties of the chimeric immunotoxins. in this investigation, the catalytic domain of shiga-like toxin (a1) was fused to human granulocyte macrophage c...

Fusion of two genes at DNA level produces a single protein, known as a chimeric protein. Immunotoxins are chimeric proteins composed of specific cell targeting and cell killing moieties. Bacterial or plant toxins are commonly used as the killing moieties of the chimeric immunotoxins. In this investigation, the catalytic domain of Shiga-like toxin (A1) was fused to human granulocyte macrophage ...

Background: Most cancer cells become resistant to anti-cancer agents. In the last few years, a new approach for targeted therapy of human cancer has been developed using immunotoxins which comprise both the cell targeting and the cell killing moieties. Methods: In the present study, the recombinant Shiga toxin A1 subunit fused to human granulocyte-macrophage colony stimulating factor (A1-GM-CSF...

Background: Immunotoxins are comprised of both the cell targeting and the cell killing moieties. We previously established a new immunotoxin, i.e. Shiga toxin granulocyte macrophage-colony stimulating factor (StxA1-GM-CSF), comprises of catalytic domain of Stx, as a killing moiety and GM-CSF, as a cell targeting moiety. In this study, the ability of the immunotoxin to induce apoptosis and dou...

background: most cancer cells become resistant to anti-cancer agents. in the last few years, a new approach for targeted therapy of human cancer has been developed using immunotoxins which comprise both the cell targeting and the cell killing moieties. methods: in the present study, the recombinant shiga toxin a1 subunit fused to human granulocyte-macrophage colony stimulating factor (a1-gm-csf...